Protalix was buoyed by the news that its late-stage trial for its Gaucher disease drug met its primary endpoint. Researchers reported that patients taking Uplyso demonstrated a significantly smaller spleen volume. Patients with the rare enzyme disorder also had smaller livers and higher hemoglobin levels after taking the drug. As Reuters notes, Protalix's success adds more pressure on Genzyme, which makes the blockbuster Cerezyme for Gaucher disease. Report